- Collaborating with operators to assist with complex regulatory issues;
- Educating teammates about compliance in day-to-day activities; and
- Navigating health care laws and the regulatory environment.
DaVita's (DVA) stock rating was reduced to 'neutral' from 'buy' at BofA/Merrill on Tuesday.
Here are Tuesday's top research calls, including an upgrade for Gilead Sciences, downgrades for Biogen and VF Corp., and new coverage for CBS.